Literature DB >> 18063610

Non-drug industry funded research.

Paolo Bruzzi.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 18063610      PMCID： PMC2174766          DOI： 10.1136/bmj.39416.559942.BE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

Authors:  H Mouridsen; M Gershanovich; Y Sun; R Pérez-Carrión; C Boni; A Monnier; J Apffelstaedt; R Smith; H P Sleeboom; F Jänicke; A Pluzanska; M Dank; D Becquart; P P Bapsy; E Salminen; R Snyder; M Lassus; J A Verbeek; B Staffler; H A Chaudri-Ross; M Dugan
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  New stars in the sky of treatment for early breast cancer.

Authors:  Martine J Piccart-Gebhart
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

3.  Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006.

Authors:  Louise Berendt; Cecilia Håkansson; Karin Friis Bach; Kim Dalhoff; Per Buch Andreasen; Lene Grejs Petersen; Elin Andersen; Henrik Enghusen Poulsen
Journal:  BMJ       Date:  2007-12-06

4.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Authors:  Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

5.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

6.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

7.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Authors:  R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245
  7 in total
  2 in total

1.  Funding a clinical trial: the perspective of a medicines funder.

Authors:  Peter Alsop; Scott Metcalfe; Jackie Evans
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Relation between the global burden of disease and randomized clinical trials conducted in Latin America published in the five leading medical journals.

Authors:  Pablo Perel; J Jaime Miranda; Zulma Ortiz; Juan Pablo Casas
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.